HTX-011
Drug300 mg bupivacaine/9 mg meloxicam
Other names: ZYNRELEF
NCT Number: NCT03907176
This is a Phase 3b, open-label study to assess postoperative opioid use in subjects undergoing unilateral open inguinal herniorrhaphy with intraoperative administration of HTX-011 and a postoperative non-opioid multimodal analgesic (MMA) regimen. The study will be conducted in 2 sequential parts: Part 1 is randomized and Part 2 is Investigator's preference for MMA regimen.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Anaheim Clinical Trials, LLC, Anaheim, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
300 mg bupivacaine/9 mg meloxicam
Other names: ZYNRELEF
Applicator for instillation
600 mg
1 g
Time frame: Through Day 15
Time frame: At discharge
Proportion of subjects who do not receive an opioid prescription at discharge (between 2 and 3 hours after surgery on average).
Time frame: Postdischarge through Day 15
Time frame: At discharge
Pain intensity scores were assessed at discharge (between 2 and 3 hours after surgery on average) using an 11-point Numeric Rating Scale (NRS) (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable". NRS scores are recorded with activity (NRS-A), sitting up from a resting position.
Time frame: Postdischarge through Day 15
Time frame: Day 15 plus or minus 2 days
The TSQM-9 contains 9 items which make up the Effectiveness, Convenience, and Global Satisfaction domains; each domain includes 3 items. Scores for each domain were computed by adding the TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100, with higher scores indicating higher satisfaction.
Heron Therapeutics
Industry
A Phase 3b, Randomized, Open-Label Study of HTX-011 as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04102267
Agnosia, Analgesia
Anaheim, California, United States
View Trial DetailsNCT07249827
Acute Pain, Agnosia
Montreal, Quebec, Canada
View Trial DetailsNCT04603638
Agnosia, Analgesia
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06282666
Acute Pain, Agnosia
Lublin, Poland
View Trial Details